August continued to show the biotech market’s resilience in the face of the COVID pandemic with one of the biggest venture fund flows for the month ever, and a half a dozen IPOs. Kymera Therapeutics was one of those August

This blog was written by Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC. A lifetime ago, in May 2020, I had the honor of writing my first “From the Trenches” blog. I

By Samantha Truex, CEO of QuenchBio, as part of the From The Trenches feature of LifeSciVC I have been privileged to read and write for this LifeSciVC blog for a handful of years now.  One of my favorite editions is

We’re half way through one of the craziest years in recent memory, with a raging viral pandemic, civil unrest and protests, staggering unemployment and economic woes, and invasive murder hornets. And yet, like the indefatigable Energizer bunny, the biotech market

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. “Hey, you know, breakdowns come. And breakdowns go. So what are you going to do about it? That’s what I’d like to know – Gumboots In an

By Deanna Petersen, chief business officer at AVROBIO, and Georgette Verdin, chief human resources officer at AVROBIO, as part of the From The Trenches feature of LifeSciVC. As we approach our 5th anniversary and surpass our 125th hire, we have

By Jodie Morrison, CEO of Cadent Therapeutics, as part of the From The Trenches feature of LifeSciVC It’s been over three months since stay at home advisories and social distancing protocols abruptly arrived in Massachusetts. Calls for a return to

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I love to travel. While still in training in internal medicine, I earned extra money to fund trips abroad by covering for community-based general

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. Manufacturing of medicines based on biology is complex. Viral vector manufacturing to produce gene therapy constructs, vaccines and oncolytic viruses is especially intricate. Most

This blog was written by Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it

This blog was written by Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC. In an environment where senior leaders are tasked with defining agile strategies in uncertain times, there are many perspectives

This blog was written by Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC. I stood in front of 15 skeptical parents and prepared to sell them on an improbable mission. They had